Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial

Published:2016-08 Issue:8 Volume:17 Page:1061-1069
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Incrocci Luca,Wortel Ruud C,Alemayehu Wendimagegn Ghidey,Aluwini Shafak,Schimmel Erik,Krol Stijn,van der Toorn Peter-Paul,Jager Hanja de,Heemsbergen Wilma,Heijmen Ben,Pos Floris

Publisher

Elsevier BV

Subject

Oncology

Reference25 articles.

1. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy;Peeters;J Clin Oncol,2006

2. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial;Dearnaley;Lancet Oncol,2007

3. Prostate cancer radiation dose response: results of the M D Anderson phase III randomized trial;Pollack;Int J Radiat Oncol Biol Phys,2002

4. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy;Peeters;Int J Radiat Oncol Biol Phys,2005

5. Prostate alpha/beta revisited: an analysis of clinical results from 14168 patients;Dasu;Acta Oncol,2012

Cited by 401 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypofractionated Dose Escalation Radiotherapy for High-risk Prostate Cancer: The Survival Analysis of the Prostate Cancer Study 5, a Groupe de Radio-oncologie Génito-urinaire du Quebec–led Phase 3 Trial;European Urology;2024-09

2. Community-Led Action Research in Oncology: Pandemic-Appropriate Radiotherapy Innovations Evaluated (CLARO PARTE) for Latin America and the Caribbean Countries;JCO Global Oncology;2024-08

3. Tolérance à court et moyen terme d’une radiothérapie prostatique hypofractionnée selon la technique du boost intégré;Cancer/Radiothérapie;2024-08

4. Escalade de dose en radiothérapie modérément hypofractionnée pour les cancers de la prostate localisés, ESHYPRO : résultats d’une série monocentrique rétrospective évaluant la toxicité et l’efficacité;Cancer/Radiothérapie;2024-08

5. Clinical and Dosimetric Comparison between Non-Image-Guided Radiation Therapy and Fiducial-Based Image-Guided Radiation Therapy with or without Reduced Margin in Intensity-Modulated Radiation Therapy for Prostate Cancer;Advances in Radiation Oncology;2024-08